Taiwan National retrospective study (2001-20) of 8732 newly Dx, biologic-naïve RA pts initiating b/tsDMARDs. Found no difference in malignancy event rates between DMARDs. 2.16% over 5-yr & 2.89% over 18yrs. (6384 Rx w/ TNFis, 667 w/ TCZ, 656 w/ ABA, 1025 on tsDMARDs) https://t.co/54ZMPywEYI